LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 3, 2026 — Longevity Medical Institute® today announced the opening of its federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory, further expanding what is now one of the most comprehensive regenerative and advanced diagnostic medical campuses in Los Cabos. [Read more…]
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BOTHELL, Wash. and Cambridge, UK, February 12, 2026 —BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing. [Read more…]
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies
Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]
TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions
Monmouth Junction, NJ and Tokyo, Japan — January 7, 2026 — TheWell Bioscience Inc., a biotechnology company pioneering next-generation animal-free biofunctional hydrogels, and PeptiGrowth Inc., a leader in innovative synthetic peptide growth factors, today announced that the two companies have entered into a Marketing Collaboration Agreement to jointly promote cutting-edge solutions for stem cell culture, organoid development, and cell therapy manufacturing. [Read more…]
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: IL-15 alternative peptide
January 6, 2026, Chiyoda-ku, Tokyo — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jun Minamitani) has successfully developed a novel synthetic peptide called “IL-15 alternative peptide” which is functionally equivalent to recombinant interleukin 15 (IL-15). This product will be on the market in December 2025. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 19
- Next Page »